DAFNA Capital Management
DAFNA Capital Management reported 87 stocks worth $468M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (21.4%), ATRC (6.3%) and CMPS (5.7%). Compared with Q2 2026, the fund opened new positions in BBOT, PYXS and QNRX, added to CMPS, NKTR and DNLI, trimmed RVMD, ATRC and XBI and sold out of MBX, ARTV and OBIO.
Latest filing: what DAFNA Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() RVMD Revolution Medicines Inc | $100M | 21.4% | 487K | −76K (−13%) | 8 of 8 | |
| 2 | ![]() ATRC Atricure Inc | $29.4M | 6.3% | 523K | −75K (−13%) | 8 of 8 | |
| 3 | ![]() CMPS Compass Pathways PLC | $26.6M | 5.7% | 2.1M | +124K (+6%) | 8 of 8 | |
| 4 | ![]() XBI Spdr Series Trust | $23.9M | 5.1% | 152K | −45K (−23%) | 8 of 8 | |
| 5 | ![]() NKTR Nektar Therapeutics | $19.6M | 4.2% | 323K | +5,000 (+2%) | 6 of 8 | |
| 6 | ![]() IDYA Ideaya Biosciences Inc | $16.9M | 3.6% | 439K | −59K (−12%) | 8 of 8 | |
| 7 | ![]() STXS Stereotaxis Inc | $16.8M | 3.6% | 13.7M | No change | 8 of 8 | |
| 8 | ![]() DNLI Denali Therapeutics Inc | $15.4M | 3.3% | 744K | +5,000 (+1%) | 7 of 8 | |
| 9 | ![]() ASND Ascendis Pharma A/s | $11.4M | 2.4% | 50K | +1,500 (+3%) | 2 of 8 | |
| 10 | ![]() RCUS Arcus Biosciences Inc | $11.4M | 2.4% | 440K | −2,000 (−0%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →DAFNA Capital Management 13F FAQ
What does DAFNA Capital Management own?
DAFNA Capital Management reported 87 stocks worth $468M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (21.4%), ATRC (6.3%) and CMPS (5.7%). The table above lists every position in the filing (the top 10 without an account).
What did DAFNA Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 4 new positions, 17 added to, 32 trimmed and 5 sold out. New positions include BBOT, PYXS and QNRX. It sold all of MBX, ARTV and OBIO.
When will DAFNA Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is DAFNA Capital Management's portfolio worth?
The Q3 2026 filing reports $468M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.























